Miricorilant
- Generic Name
- Miricorilant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23F3N2O2
- CAS Number
- 1400902-13-7
- Unique Ingredient Identifier
- 311Y5GV21M
- Background
Miricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent Weight Gain While Taking Antipsychotic Medications (GRATITUDE)).
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant
- Conditions
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 26
- Registration Number
- NCT05712265
- Locations
- ๐บ๐ธ
Site 01, Miami, Florida, United States
Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT05553470
- Locations
- ๐บ๐ธ
Site 02, Miami Lakes, Florida, United States
๐บ๐ธSite 01, Miami, Florida, United States
Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo
- Conditions
- Interventions
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- The Scripps Research Institute
- Target Recruit Count
- 50
- Registration Number
- NCT04466215
- Locations
- ๐บ๐ธ
The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research, La Jolla, California, United States
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)
- Conditions
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT03823703
- Locations
- ๐บ๐ธ
Site 208, Glendale, Arizona, United States
๐บ๐ธSite 234, Port Orange, Florida, United States
๐บ๐ธSite 215, Edinburg, Texas, United States
This Phase 2, Double Blind, Placebo-controlled, Randomized Study is to Assess the Safety and Efficacy of Miricorilant in Obese Adult With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications.
- Conditions
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 71
- Registration Number
- NCT03818256
- Locations
- ๐บ๐ธ
Site 239, Garden Grove, California, United States
๐บ๐ธSite 143, Bentonville, Arkansas, United States
๐บ๐ธSite 249, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.